Estrone and Estradiol Levels in Breast Cancer Patients Using Anastrozole Are Not Related to Body Mass Index

Detalhes bibliográficos
Autor(a) principal: Coscia,Eduardo Borges
Data de Publicação: 2017
Outros Autores: Sabha,Maricene, Gerenutti,Marli, Groppo,Francisco Carlos, Bergamaschi,Cristiane de Cássia
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Revista brasileira de ginecologia e obstetrícia (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-72032017000100014
Resumo: ABSTRACT Objective: Obesity is associated with an increased risk for breast cancer. Recent studies have shown that aromatase inhibitors may be less effective in women with a high body mass index (BMI). The aim of this study was to establish the relationship between the BMI and plasma estrone and estradiol levels in postmenopausal women with hormone receptor-positive breast cancer using anastrozole. Methods: In this cohort study, the patients were divided into three groups according to BMI (normal weight, overweight and obese) to compare and correlate plasma hormone levels before starting anastrozole hormone therapy and three months after treatment. Plasma hormone levels were compared for age and use of chemotherapy. Results: A statistically significant reduction in estrone and estradiol levels was observed between baseline and three months after starting the anastrozole treatment (p < 0.05). There was no statistically significant difference in plasma estrone and estradiol levels among the BMI groups (p > 0.05), but a significant reduction in plasma estrone levels was observed after three-months' treatment relative to baseline in all groups, as well as a reduction in estradiol in the obese group (p < 0.05). The use of chemotherapy and age > 65 years had no influence on plasma steroid levels. Conclusion: Changes in estrone and estradiol levels in the studied groups were not associated with BMI, chemotherapy or age.
id FEBRASGO-1_a0aad8c8c110a1f49dfbfac4cf962657
oai_identifier_str oai:scielo:S0100-72032017000100014
network_acronym_str FEBRASGO-1
network_name_str Revista brasileira de ginecologia e obstetrícia (Online)
repository_id_str
spelling Estrone and Estradiol Levels in Breast Cancer Patients Using Anastrozole Are Not Related to Body Mass Indexbreast neoplasmsestroneestradiolbody mass indexanastrozoleABSTRACT Objective: Obesity is associated with an increased risk for breast cancer. Recent studies have shown that aromatase inhibitors may be less effective in women with a high body mass index (BMI). The aim of this study was to establish the relationship between the BMI and plasma estrone and estradiol levels in postmenopausal women with hormone receptor-positive breast cancer using anastrozole. Methods: In this cohort study, the patients were divided into three groups according to BMI (normal weight, overweight and obese) to compare and correlate plasma hormone levels before starting anastrozole hormone therapy and three months after treatment. Plasma hormone levels were compared for age and use of chemotherapy. Results: A statistically significant reduction in estrone and estradiol levels was observed between baseline and three months after starting the anastrozole treatment (p < 0.05). There was no statistically significant difference in plasma estrone and estradiol levels among the BMI groups (p > 0.05), but a significant reduction in plasma estrone levels was observed after three-months' treatment relative to baseline in all groups, as well as a reduction in estradiol in the obese group (p < 0.05). The use of chemotherapy and age > 65 years had no influence on plasma steroid levels. Conclusion: Changes in estrone and estradiol levels in the studied groups were not associated with BMI, chemotherapy or age.Federação Brasileira das Sociedades de Ginecologia e Obstetrícia2017-01-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-72032017000100014Revista Brasileira de Ginecologia e Obstetrícia v.39 n.1 2017reponame:Revista brasileira de ginecologia e obstetrícia (Online)instname:Federação Brasileira das Sociedades de Ginecologia e Obstetrícia (FEBRASGO)instacron:FEBRASGO10.1055/s-0036-1597974info:eu-repo/semantics/openAccessCoscia,Eduardo BorgesSabha,MariceneGerenutti,MarliGroppo,Francisco CarlosBergamaschi,Cristiane de Cássiaeng2017-04-10T00:00:00Zoai:scielo:S0100-72032017000100014Revistahttp://www.scielo.br/rbgohttps://old.scielo.br/oai/scielo-oai.phppublicações@febrasgo.org.br||rbgo@fmrp.usp.br1806-93390100-7203opendoar:2017-04-10T00:00Revista brasileira de ginecologia e obstetrícia (Online) - Federação Brasileira das Sociedades de Ginecologia e Obstetrícia (FEBRASGO)false
dc.title.none.fl_str_mv Estrone and Estradiol Levels in Breast Cancer Patients Using Anastrozole Are Not Related to Body Mass Index
title Estrone and Estradiol Levels in Breast Cancer Patients Using Anastrozole Are Not Related to Body Mass Index
spellingShingle Estrone and Estradiol Levels in Breast Cancer Patients Using Anastrozole Are Not Related to Body Mass Index
Coscia,Eduardo Borges
breast neoplasms
estrone
estradiol
body mass index
anastrozole
title_short Estrone and Estradiol Levels in Breast Cancer Patients Using Anastrozole Are Not Related to Body Mass Index
title_full Estrone and Estradiol Levels in Breast Cancer Patients Using Anastrozole Are Not Related to Body Mass Index
title_fullStr Estrone and Estradiol Levels in Breast Cancer Patients Using Anastrozole Are Not Related to Body Mass Index
title_full_unstemmed Estrone and Estradiol Levels in Breast Cancer Patients Using Anastrozole Are Not Related to Body Mass Index
title_sort Estrone and Estradiol Levels in Breast Cancer Patients Using Anastrozole Are Not Related to Body Mass Index
author Coscia,Eduardo Borges
author_facet Coscia,Eduardo Borges
Sabha,Maricene
Gerenutti,Marli
Groppo,Francisco Carlos
Bergamaschi,Cristiane de Cássia
author_role author
author2 Sabha,Maricene
Gerenutti,Marli
Groppo,Francisco Carlos
Bergamaschi,Cristiane de Cássia
author2_role author
author
author
author
dc.contributor.author.fl_str_mv Coscia,Eduardo Borges
Sabha,Maricene
Gerenutti,Marli
Groppo,Francisco Carlos
Bergamaschi,Cristiane de Cássia
dc.subject.por.fl_str_mv breast neoplasms
estrone
estradiol
body mass index
anastrozole
topic breast neoplasms
estrone
estradiol
body mass index
anastrozole
description ABSTRACT Objective: Obesity is associated with an increased risk for breast cancer. Recent studies have shown that aromatase inhibitors may be less effective in women with a high body mass index (BMI). The aim of this study was to establish the relationship between the BMI and plasma estrone and estradiol levels in postmenopausal women with hormone receptor-positive breast cancer using anastrozole. Methods: In this cohort study, the patients were divided into three groups according to BMI (normal weight, overweight and obese) to compare and correlate plasma hormone levels before starting anastrozole hormone therapy and three months after treatment. Plasma hormone levels were compared for age and use of chemotherapy. Results: A statistically significant reduction in estrone and estradiol levels was observed between baseline and three months after starting the anastrozole treatment (p < 0.05). There was no statistically significant difference in plasma estrone and estradiol levels among the BMI groups (p > 0.05), but a significant reduction in plasma estrone levels was observed after three-months' treatment relative to baseline in all groups, as well as a reduction in estradiol in the obese group (p < 0.05). The use of chemotherapy and age > 65 years had no influence on plasma steroid levels. Conclusion: Changes in estrone and estradiol levels in the studied groups were not associated with BMI, chemotherapy or age.
publishDate 2017
dc.date.none.fl_str_mv 2017-01-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-72032017000100014
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-72032017000100014
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1055/s-0036-1597974
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Federação Brasileira das Sociedades de Ginecologia e Obstetrícia
publisher.none.fl_str_mv Federação Brasileira das Sociedades de Ginecologia e Obstetrícia
dc.source.none.fl_str_mv Revista Brasileira de Ginecologia e Obstetrícia v.39 n.1 2017
reponame:Revista brasileira de ginecologia e obstetrícia (Online)
instname:Federação Brasileira das Sociedades de Ginecologia e Obstetrícia (FEBRASGO)
instacron:FEBRASGO
instname_str Federação Brasileira das Sociedades de Ginecologia e Obstetrícia (FEBRASGO)
instacron_str FEBRASGO
institution FEBRASGO
reponame_str Revista brasileira de ginecologia e obstetrícia (Online)
collection Revista brasileira de ginecologia e obstetrícia (Online)
repository.name.fl_str_mv Revista brasileira de ginecologia e obstetrícia (Online) - Federação Brasileira das Sociedades de Ginecologia e Obstetrícia (FEBRASGO)
repository.mail.fl_str_mv publicações@febrasgo.org.br||rbgo@fmrp.usp.br
_version_ 1754115943590526976